Chongqing Genrix Biopharmaceutical (SHA:688443) initiated phase three clinical trial for its GR1802 injection to target chronic spontaneous urticaria.
Chronic spontaneous urticaria is the third indication to enter phase three trials, joining atopic dermatitis and chronic sinusitis with nasal polyps, according to a Friday filing with the Shanghai bourse.
Shares of the antibody drug maker closed 4% higher Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments